LYON, France, Feb. 22, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the patient awareness program to facilitate enrollment in the ENLIGHT trial has launched. The ENLIGHT study is a multi-center Phase II/III clinical trial testing EDAP’s Ablatherm-HIFU (high-intensity focused ultrasound) for the treatment of localized prostate cancer. The program, led by Fleishman-Hillard’s Clinical Trials Division, consists of a patient Web site, a centralized call center, and site recruitment tool kits that provide detailed information for both patients and physicians.
